

GenCore version 5.1.4\_p5\_4578  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 16, 2003, 12:10:40 ; Search time 36 Seconds

(without alignments)  
440.467 Million cell updates/sec

Title: US-10-015-967-2

Perfect score: 644  
Sequence: 1 MKVLISLLLLPLMLSMV.....SRACQFLKQCLRSFALPL 119

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 08  
Maximum Match 100%

Listing first 45 summaries

Database : A\_Geneseq\_101002:\*

1: /SID2/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:\*  
2: /SID2/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:\*  
3: /SID2/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:\*  
4: /SID2/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:\*  
5: /SID2/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:\*  
6: /SID2/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:\*  
7: /SID2/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:\*  
8: /SID2/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:\*  
9: /SID2/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:\*  
10: /SID2/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:\*  
11: /SID2/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:\*  
12: /SID2/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:\*  
13: /SID2/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:\*  
14: /SID2/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:\*  
15: /SID2/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:\*  
16: /SID2/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:\*  
17: /SID2/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:\*  
18: /SID2/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:\*  
19: /SID2/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:\*  
20: /SID2/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:\*  
21: /SID2/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:\*  
22: /SID2/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:\*  
23: /SID2/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	644	100.0	119	21	Human secreted pro
2	644	100.0	119	21	Human TGC-440 secr
3	644	100.0	119	21	Human signal pepti
4	644	100.0	119	21	Membrane-bound pro
5	644	100.0	119	22	Human PRO polypept
6	644	100.0	119	22	Amino acid sequenc
7	644	100.0	119	22	Human PRO442. Hom
8	644	100.0	119	22	Human PRO842 (UN04
9	548	85.1	97	21	Mature human TGC-4
10	527	81.8	93	19	Polypeptide encode

11	456	70.8	119	21	AA182457
12	386	59.9	97	21	AA182458
13	386	59.9	119	21	AA182455
14	358	55.6	69	20	AA11732
15	342	53.1	97	21	AA182456
16	296	46.0	64	19	AA183928
17	225	34.9	48	20	AA111731
18	78.5	12.2	191	22	AA066308
19	73.5	11.4	70	14	AA191996
20	73.5	11.4	70	14	AA191996
21	71.5	11.1	108	23	AA021337
22	71	11.0	330	22	ABG25331
23	71	11.0	1798	19	AA150896
24	71	11.0	3190	22	AA184634
25	71	11.0	3275	22	AB170437
26	70.5	10.9	146	23	AA183095
27	70	10.9	117	23	AB161841
28	70	10.9	121	20	AA166185
29	70	10.9	121	21	AA166185
30	70	10.9	167	21	AA166185
31	70	10.9	167	21	AA166185
32	70	10.9	167	21	AA166185
33	70	10.9	167	21	AA166185
34	70	10.9	167	21	AA166185
35	70	10.9	167	21	AA166185
36	70	10.9	167	21	AA166185
37	70	10.9	167	21	AA166185
38	70	10.9	167	21	AA166185
39	70	10.9	167	21	AA166185
40	70	10.9	167	21	AA166185
41	70	10.9	167	21	AA166185
42	70	10.9	167	21	AA166185
43	70	10.9	167	21	AA166185
44	70	10.9	167	21	AA166185
45	70	10.9	167	21	AA166185

## ALIGNMENTS

RESULT 1	AA1834728
ID	AA1834728 standard; Protein; 119 AA.
XX	AA1834728:
XX	26-JAN-2001 (first entry)
DE	Human secreted protein encoded by DNA clone vq8 1.
KW	Secreted protein; human; autoimmune disorder; multiple sclerosis; ulcer;
KW	systemic lupus erythematosus; rheumatoid arthritis; anaemia; stroke;
KW	haematoiposis regulation; tissue regrowth; wound healing; haemophilia;
KW	Alzheimer's disease; Parkinson's disease; Shy-dreger syndrome; cancer;
KW	contractile; infection; growth inhibition; hyperproliferative disorder;
OS	poriasis.
XX	Homo sapiens.
XX	WO200055375-A1.
XX	21-SEP-2000.
XX	17-MAR-2000; 2000MO-US07285.
XX	17-MAR-1999; 99US-0124808.
XX	17-MAR-1999; 99US-0124916.
XX	17-AUG-1999; 99US-0149639.
XX	01-OCT-1999; 99US-0157247.
XX	29-NOV-1999; 99US-0167824.
XX	15-FEB-2000; 2000US-0182711.
XX	(ALPH-) ALPHAGEN INC.

Mouse TGC-440 secr
Mature mouse TGC-4
Rat TGC-440 secret
Human 5' EST secre
Mature rat TGC-440
Human secreted pro
Human 5' EST secre
Propionibacterium
Part of chick vita
Chicken vitamin D
Arabidopsis thaila
Novel human diagno
Human laminin B2 c
Amino acid sequenc
Drosophila melanog
Novel secreted pro
Prostate cancer-as
Human bladder tumo
Human prostate can
Human growth facto
Human PRO834 matur
Fibrosarcoma vascu
Vascular endothell
Parapox virus VEGF
Human vascular end
Human VEGF protein
Human PRO834 prove
Polypeptide for hu
Human vascular end
Human VEGF-B167 pr
Human vascular end
Hexa-His-tagged hu
Human ovarian anti
Physcomitrella pat
Drosophila melanog

XX Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;  
 PI WPI; 2000-638211/61.  
 XX N-PSDB; AAC59829.  
 DR  
 XX  
 PT Novel proteins and polypeptides useful for the treatment of e.g.  
 PT multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis,  
 PT cancer, Alzheimer's disease, Parkinson's disease, stroke, anemia and  
 PT ulcers

Claim 92: Page 441-442; 493pp; English.

XX This invention relates to 59 human secreted proteins and the nucleotide  
 CC sequences encoding them. Sequences AAC59788-C59846 and AAB34687-B34745  
 CC represent the proteins and their encoding nucleotide sequences, and  
 CC sequences AAB34746-B34771 represent fragments of the proteins. Probes  
 CC for the DNA sequences are represented by sequences AAC59847-C599596. The  
 CC proteins exhibit neuroprotective, dermatological, immunosuppressive,  
 CC antiinflammatory, antianemic, nootropic, antiparkinsonian,  
 CC cerebroprotective, hemostatic, vulnery, cytostatic, antipsoriatic,  
 CC antibacterial, virucide, and fungicide activity. The proteins and  
 CC nucleotide sequences are useful as nutritional sources or supplements  
 CC and in research. The proteins are useful for treating immune deficiency  
 CC and disorders, which may be genetic or resulting from infections,  
 CC autoimmune disorders such as multiple sclerosis, systemic lupus  
 CC erythematosus, rheumatoid arthritis, and for treating myeloid or lymphoid  
 CC cell deficiencies such as anaemias by regulating haematopoiesis. The  
 CC proteins are also useful in compositions for bone, cartilage, tendon,  
 CC ligament and/or nerve tissue growth or regeneration, for wound healing,  
 CC tissue repair and replacement and in the treatment of central and  
 CC and ulcers. Other uses include in the treatment of wounds, incisions  
 CC and peripheral nervous system and neuropathies such as Alzheimer's and  
 CC Parkinson's diseases and Shy-Drager syndrome, and mechanical and  
 CC traumatic disorders, such as spinal cord disorders, head trauma and  
 CC stroke. The proteins may also be used as a contraceptive, and for  
 CC treating coagulation disorders such as haemophilias. The protein and  
 CC nucleotide sequences with cadherin activity are useful for treating  
 CC cancer. Other uses for the protein include for inhibiting the growth,  
 CC infection or function of, or killing, infectious agents such as bacteria,  
 CC virus, fungi and other parasites, for effecting bodily characteristics  
 CC such as height, weight, hair colour, effecting biorythms or cardiac  
 CC cycles or rhythms, effecting metabolism, catabolism, anabolism,  
 CC processing, utilization, storage or elimination of dietary fat, lipid,  
 CC protein, carbohydrate, vitamins, minerals, cofactors, effecting  
 CC behavioural characteristics, providing analgesic effects and for treating  
 CC hyperproliferative disorders such as psoriasis.

XX Sequence 119 AA:

Query Match 100.0%; Score 644; DB 21; Length 119;  
 Best Local Similarity 100.0%; Pred. No. 1.7e-66;  
 Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRGQASRRWLQEGGQECCKDWFLRAP 60  
 DB 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRGQASRRWLQEGGQECCKDWFLRAP 60  
 OY 61 RRFKMTVSGLPKKQPCDHFGRGNVKKTRHQRHRRKPKNHSRACQFLKQCLRSFALPL 119  
 DB 61 RRFKMTVSGLPKKQPCDHFGRGNVKKTRHQRHRRKPKNHSRACQFLKQCLRSFALPL 119

RESULT 2

AA82453 standard; Protein: 119 AA.

XX AA82453;  
 AC  
 XX  
 DT 30-JUN-2000 (first entry)  
 XX  
 DE Human TGC-440 secretory protein SEQ ID NO:1.  
 XX

KW TGC-440: secretory protein; immunological disease; infectious disease;  
 KW pulmonary function disorder; hepatic function disorder; nephrotropic;  
 KW gastrointestinal function disorder; antiinflammatory; immunomodulatory;  
 KW virucide; hepatotropic; antiasthmatic; antibacterial; vaccine;  
 KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;  
 KW pneumonia; Helicobacter pylori infection.

XX Homo sapiens.

XX W0200014226-A1.

XX 16-MAR-2000.

XX 02-SEP-1999: 99WO-JP04765.

XX 03-SEP-1998: 98JP-0250108.

XX (TAKE ) TAKEDA CHEM IND LTD.

XX Itoh Y, Ogi K, Tanaka H, Kitada C;

XX WPI; 2000-256978/22.

XX N-PSDB; AAA08343, AAA08344.

XX Secretory protein TGC440, antibodies to it and compounds promoting or  
 PT inhibiting its activity for diagnosis and treatment of diseases of the  
 PT immune system, lung, kidney, liver and intestinal system

XX Claim 1; Fig 1; 86pp; Japanese.

XX The present sequence represents a human secretory protein designated  
 CC TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,  
 CC virucide, hepatotropic, antiasthmatic and antibacterial activities,  
 CC and can be used in vaccines. TGC-440 and the polynucleotide sequence  
 CC encoding it can be used to treat, prevent and diagnose immunological,  
 CC lung, liver, kidney or gastrointestinal disorders and infectious  
 CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,  
 CC pulmonary hypertension, and Helicobacter pylori infection. An antibody  
 CC immunospecific for TGC-440 is also useful in the above treatment and  
 CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid  
 CC specimen.

XX Sequence 119 AA:

Query Match 100.0%; Score 644; DB 21; Length 119;  
 Best Local Similarity 100.0%; Pred. No. 1.7e-66;  
 Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRGQASRRWLQEGGQECCKDWFLRAP 60  
 DB 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRGQASRRWLQEGGQECCKDWFLRAP 60  
 OY 61 RRFKMTVSGLPKKQPCDHFGRGNVKKTRHQRHRRKPKNHSRACQFLKQCLRSFALPL 119  
 DB 61 RRFKMTVSGLPKKQPCDHFGRGNVKKTRHQRHRRKPKNHSRACQFLKQCLRSFALPL 119

RESULT 3

AA87317 standard; Protein: 119 AA.

XX AA87317;

XX 11-MAY-2000 (first entry)

XX Human signal peptide containing protein HSP-94 SEQ ID NO:94.

XX Human; signal peptide-containing protein; HSP; diagnosis; cancer;  
 KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;  
 KW antimicrobial; nootropic; neuroprotective; cardiovascular; hepatotropic;  
 KW antiasthmatic; gene therapy; cell proliferation; neurological disorder;  
 KW reproductive disorder; developmental disorder; arteriosclerosis;  
 KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;

asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;  
Parkinson's disease; Huntington's diseases; ovulatory defect;  
muscular dystrophy.  
XX  
OS Homo sapiens.  
XX  
PN WO200000610-A2.  
XX  
PD 06-JAN-2000.  
XX  
PF 25-JUN-1999; 99WO-US14484.  
XX  
PR 26-JUN-1998; 98US-0090762.  
PR 31-JUL-1998; 98US-0094983.  
PR 01-OCT-1998; 98US-0102686.  
PR 11-DEC-1998; 98US-0112129.  
XX  
PA (INCYTE PHARM INC.  
XX  
PI Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;  
PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;  
PI Bandman O;  
XX  
DR WPI: 2000-160673/14.  
XX  
PS N-PSDB: AA298202.  
XX  
XX  
PS Claim 1; Page 220-221; 327pp; English.  
XX  
CC AA298109 to AA298242 encode AAY87224 to AAY87357 which represent the  
CC human signal peptide-containing proteins HSP-1 to HSP-134. HSPs have  
CC anticancer, anti-inflammatory, antimicrobial, nootropic, hepatotropic,  
CC neuroprotective, cardiovascular and antistatic activities, and can  
CC be used in gene therapy. HSPs can be used to treat or prevent disorders  
CC associated with decreased activity or function of HSP. Antagonists of  
CC HSP are used to treat or prevent disorders associated with increased  
CC activity or function of HSP. Such diseases include cell proliferation  
CC (including cancer), inflammation, cardiovascular, neurological,  
CC reproductive or developmental disorders, (e.g. arteriosclerosis,  
CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,  
CC asthma, Crohn's disease, microbial or other infections, congestive or  
CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's  
CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSP  
CC nucleic acids can be used for the recombinant production of HSP, for  
CC detecting HSP in standard hybridisation and amplification assays (for  
CC diagnosis and monitoring), in gene therapy, as antisense,  
CC triplex-forming or ribozyme therapeutics, for detecting related sequences  
CC or genetic variations, and for chromosomal mapping. HSP are also used to  
CC raise specific antibodies (Ab) and to screen for agonists and  
CC antagonists (potential therapeutic agents). Ab are used to diagnose, or  
CC monitor, HSP-related diseases (in usual immunoassays), as therapeutic  
CC antagonists, in competitive drug screens, and for purification of HSP  
CC from natural sources.  
XX  
SQ Sequence 119 AA:  
Query Match 100.0%; Score 644; DB 21; Length 119;  
Best Local Similarity 100.0%; Pred. No. 1,7e-66;  
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

AA66668  
ID AA66668 standard; protein; 119 AA.  
XX  
AC AA66668;  
XX  
DT 05-APR-2000 (first entry)  
XX  
DE Membrane-bound protein PRO842.  
XX  
KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;  
KW pharmacological; receptor immunoassay; gene mapping.  
XX  
OS Homo sapiens.  
XX  
PN WO963088-A2.  
XX  
PD 09-DEC-1999.  
XX  
PF 02-JUN-1999; 99WO-US12252.  
XX  
PR 02-JUN-1998; 98US-0087607.  
PR 02-JUN-1998; 98US-0087609.  
PR 02-JUN-1998; 98US-0087759.  
PR 03-JUN-1998; 98US-0087827.  
PR 04-JUN-1998; 98US-0088021.  
PR 04-JUN-1998; 98US-0088025.  
PR 04-JUN-1998; 98US-0088028.  
PR 04-JUN-1998; 98US-0088029.  
PR 04-JUN-1998; 98US-0088030.  
PR 04-JUN-1998; 98US-0088033.  
PR 04-JUN-1998; 98US-0088326.  
PR 05-JUN-1998; 98US-0088167.  
PR 05-JUN-1998; 98US-0088202.  
PR 05-JUN-1998; 98US-0088212.  
PR 05-JUN-1998; 98US-0088217.  
PR 09-JUN-1998; 98US-0088655.  
PR 10-JUN-1998; 98US-0088722.  
PR 10-JUN-1998; 98US-0088730.  
PR 10-JUN-1998; 98US-0088734.  
PR 10-JUN-1998; 98US-0088738.  
PR 10-JUN-1998; 98US-0088740.  
PR 10-JUN-1998; 98US-0088741.  
PR 10-JUN-1998; 98US-0088742.  
PR 10-JUN-1998; 98US-0088810.  
PR 10-JUN-1998; 98US-0088811.  
PR 10-JUN-1998; 98US-0088824.  
PR 10-JUN-1998; 98US-0088825.  
PR 10-JUN-1998; 98US-0088826.  
PR 11-JUN-1998; 98US-0088858.  
PR 11-JUN-1998; 98US-0088861.  
PR 11-JUN-1998; 98US-0088863.  
PR 11-JUN-1998; 98US-0088876.  
PR 12-JUN-1998; 98US-0089090.  
PR 12-JUN-1998; 98US-0089105.  
PR 16-JUN-1998; 98US-0089440.  
PR 16-JUN-1998; 98US-0089512.  
PR 16-JUN-1998; 98US-0089514.  
PR 17-JUN-1998; 98US-0089532.  
PR 17-JUN-1998; 98US-0089538.  
PR 17-JUN-1998; 98US-0089598.  
PR 17-JUN-1998; 98US-0089599.  
PR 17-JUN-1998; 98US-0089600.  
PR 17-JUN-1998; 98US-0089653.  
PR 18-JUN-1998; 98US-0089801.  
PR 18-JUN-1998; 98US-0089807.  
PR 18-JUN-1998; 98US-0089908.  
PR 19-JUN-1998; 98US-0089947.  
PR 19-JUN-1998; 98US-0089948.  
PR 19-JUN-1998; 98US-0089952.  
PR 22-JUN-1998; 98US-0090246.  
PR 22-JUN-1998; 98US-0090252.  
PR 22-JUN-1998; 98US-0090254.  
PR 23-JUN-1998; 98US-0090349.

```

PR 23-JUN-1998; 98US-0090355.
PR 24-JUN-1998; 98US-0090429.
PR 24-JUN-1998; 98US-0090431.
PR 24-JUN-1998; 98US-0090435.
PR 24-JUN-1998; 98US-0090444.
PR 24-JUN-1998; 98US-0090445.
PR 24-JUN-1998; 98US-0090461.
PR 24-JUN-1998; 98US-0090472.
PR 24-JUN-1998; 98US-0090535.
PR 24-JUN-1998; 98US-0090538.
PR 24-JUN-1998; 98US-0090540.
PR 24-JUN-1998; 98US-0090557.
PR 25-JUN-1998; 98US-0090676.
PR 25-JUN-1998; 98US-0090678.
PR 25-JUN-1998; 98US-0090688.
PR 25-JUN-1998; 98US-0090690.
PR 25-JUN-1998; 98US-0090691.
PR 25-JUN-1998; 98US-0090694.
PR 25-JUN-1998; 98US-0090695.
PR 25-JUN-1998; 98US-0090696.
PR 26-JUN-1998; 98US-0090862.
PR 26-JUN-1998; 98US-0090863.
PR 01-JUL-1998; 98US-0091358.
PR 01-JUL-1998; 98US-0091360.
PR 01-JUL-1998; 98US-0091544.
PR 02-JUL-1998; 98US-0091478.
PR 02-JUL-1998; 98US-0091486.
PR 02-JUL-1998; 98US-0091519.
PR 02-JUL-1998; 98US-0091626.
PR 02-JUL-1998; 98US-0091628.
PR 02-JUL-1998; 98US-0091633.
PR 02-JUL-1998; 98US-0091646.
PR 07-JUL-1998; 98US-0091673.
PR 07-JUL-1998; 98US-0091978.
PR 09-JUL-1998; 98US-0091982.
PR 10-JUL-1998; 98US-0092472.
PR 20-JUL-1998; 98US-0093339.
PR 30-JUL-1998; 98US-0094651.
PR 04-AUG-1998; 98US-0095282.
PR 04-AUG-1998; 98US-0095285.
PR 04-AUG-1998; 98US-0095301.
PR 04-AUG-1998; 98US-0095302.
PR 04-AUG-1998; 98US-0095318.
PR 04-AUG-1998; 98US-0095321.
PR 04-AUG-1998; 98US-0095325.
PR 10-AUG-1998; 98US-0095916.
PR 10-AUG-1998; 98US-0095929.
PR 10-AUG-1998; 98US-0096012.
PR 11-AUG-1998; 98US-0096143.
PR 11-AUG-1998; 98US-0096146.
PR 12-AUG-1998; 98US-0096329.
PR 17-AUG-1998; 98US-0096757.
PR 17-AUG-1998; 98US-0096766.
PR 17-AUG-1998; 98US-0096768.
PR 17-AUG-1998; 98US-0096773.
PR 17-AUG-1998; 98US-0096791.
PR 17-AUG-1998; 98US-0096867.
PR 17-AUG-1998; 98US-0096891.
PR 17-AUG-1998; 98US-0096894.
PR 17-AUG-1998; 98US-0096895.
PR 17-AUG-1998; 98US-0096897.
PR 18-AUG-1998; 98US-0096949.
PR 18-AUG-1998; 98US-0096950.
PR 18-AUG-1998; 98US-0096959.
PR 18-AUG-1998; 98US-0096960.
PR 18-AUG-1998; 98US-0097022.
PR 19-AUG-1998; 98US-0097141.
PR 20-AUG-1998; 98US-0097218.
PR 24-AUG-1998; 98US-0097661.
PR 26-AUG-1998; 98US-0097951.
PR 26-AUG-1998; 98US-0097952.
PR 26-AUG-1998; 98US-0097954.

PR 26-AUG-1998; 98US-0097955.
PR 26-AUG-1998; 98US-0097971.
PR 26-AUG-1998; 98US-0097974.
PR 26-AUG-1998; 98US-0097978.
PR 26-AUG-1998; 98US-0097979.
PR 26-AUG-1998; 98US-0097986.
PR 26-AUG-1998; 98US-0098014.
PR 31-AUG-1998; 98US-0098525.
PR 16-SEP-1998; 98US-0100634.
PR 12-JAN-1999; 99US-0115565.

PA (GETH ) GENENTECH INC.
XX
XX Baker K, Chen J, Goddard A, Gurney AL, Smith V, Matanabe CK;
PI Wood WI, Yuan J;
XX
XX WPI, 2000-072883/06.
DR N-PSDB; AAZ65001.
XX
XX Membrane-bound proteins and related nucleotide sequences -
PT
XX
XX claim 12; Fig 99; 822pp; English.
PS
XX
XX The invention provides membrane-bound PRO polypeptides and
CC polynucleotides encoding them. The PRO sequences of the invention were
CC identified based on extracellular domain homology screening. The PRO
CC sequences have homology with proteins including LDL receptors, TIE
CC ligands and various enzymes. The membrane-bound proteins and receptor
CC molecules are useful as pharmaceutical and diagnostic agents. Receptor
CC immunoadhesins, for instance, can be used as therapeutic agents to block
CC receptor-ligand interactions. The membrane-bound proteins can also be
CC employed for screening of potential peptide or small molecule inhibitors
CC of the relevant receptor/ligand interaction. The PRO encoding sequences
CC are useful as hybridization probes, in chromosome and gene mapping and in
CC the generation of antisense RNA and DNA. PRO nucleic acid sequences
CC will also be useful for the preparation of PRO polypeptides, especially
CC by recombinant techniques.
XX
XX Sequence 119 AA:

SQ
Query Match 100.0%; Score 644; DB 21; Length 119;
Best Local Similarity 100.0%; Pred. No. 1,7e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISLILLLPLIMLSWSSSLNPGVARGHRRGQASRRMLQSGGCECKDMFLRAP 60
DB 1 MKVLISLILLLPLIMLSWSSSLNPGVARGHRRGQASRRMLQSGGCECKDMFLRAP 60
QY 61 RREKMTVSGLPKKQCPDHFHKGAVKTRHQRHRRKPNKHSRACQDFLQCOLRSPALPL 119
DB 61 RREKMTVSGLPKKQCPDHFHKGAVKTRHQRHRRKPNKHSRACQDFLQCOLRSPALPL 119

RESULT 5
AAU29093
ID AAU29093 standard; Protein; 119 AA.
XX
XX AAU29093;
AC
XX
XX 18-DEC-2001 (first entry)
DT
XX
XX Human PRO polypeptide sequence #70.
DE
XX
XX PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
KW dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
KW blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
KW adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.
XX
XX Homo sapiens.
OS
XX
XX WO20016848-A2.
XX
XX 20-SEP-2001.
PD

```

XX 28-FEB-2001; 2001WO-US06520.  
XX  
PR 01-MAR-2000; 2000WO-US05601.  
PR 02-MAR-2000; 2000WO-US05841.  
PR 03-MAR-2000; 2000US-187202P.  
PR 06-MAR-2000; 2000US-186368P.  
PR 14-MAR-2000; 2000US-189320P.  
PR 14-MAR-2000; 2000US-189328P.  
PR 15-MAR-2000; 2000WO-US06884.  
PR 21-MAR-2000; 2000US-190828P.  
PR 21-MAR-2000; 2000US-191007P.  
PR 21-MAR-2000; 2000US-191048P.  
PR 21-MAR-2000; 2000US-191314P.  
PR 28-MAR-2000; 2000US-192655P.  
PR 29-MAR-2000; 2000US-193032P.  
PR 29-MAR-2000; 2000US-193053P.  
PR 30-MAR-2000; 2000WO-US08439.  
PR 04-APR-2000; 2000US-194449P.  
PR 04-APR-2000; 2000US-194647P.  
PR 11-APR-2000; 2000US-195975P.  
PR 11-APR-2000; 2000US-196000P.  
PR 11-APR-2000; 2000US-196187P.  
PR 11-APR-2000; 2000US-196690P.  
PR 11-APR-2000; 2000US-196820P.  
PR 18-APR-2000; 2000US-198121P.  
PR 18-APR-2000; 2000US-198585P.  
PR 25-APR-2000; 2000US-199397P.  
PR 25-APR-2000; 2000US-199550P.  
PR 25-APR-2000; 2000US-199654P.  
PR 03-MAY-2000; 2000US-201516P.  
PR 17-MAY-2000; 2000WO-US13705.  
PR 22-MAY-2000; 2000WO-US14042.  
PR 30-MAY-2000; 2000WO-US14941.  
PR 02-JUN-2000; 2000WO-US15264.  
PR 05-JUN-2000; 2000US-209832P.  
PR 28-JUL-2000; 2000WO-US20710.  
PR 22-AUG-2000; 2000US-0644848.  
PR 24-AUG-2000; 2000WO-US23328.  
PR 08-NOV-2000; 2000WO-US30952.  
PR 01-DEC-2000; 2000WO-US32678.  
PR 20-DEC-2000; 2000WO-US34956.  
XX  
PA (GENENTECH INC.  
XX  
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PT, Gurney AL;  
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2001-602746/68.  
XX  
DR N-PSDB; AAS45594.  
XX  
PT Novel nucleic acids encoding PRO polypeptides, used to diagnose the  
PT presence of tumours, such as prostate and breast tumours, in mammals and  
PT to screen for modulators of the compounds -  
XX  
PS Claim 11; Fig 140; 774pp; English.  
XX  
CC Sequences AAU99024-AAU92328 represent PRO polypeptides of the invention.  
CC The PRO polypeptides and their associated nucleic acids can be used to  
CC detect the presence of a tumour in a mammal by comparing the level of  
CC expression of a PRO polypeptide in a test sample of cells from the animal  
CC and a control sample of normal cells, whereby a higher level of  
CC expression in the test sample indicates the presence of a tumour in the  
CC mammal. Mammals include dogs, cats, cattle, horses, sheep, pigs, goats  
CC and rabbits but are preferably human. The polypeptides can be used to  
CC stimulate tumour necrosis factor (TNF) alpha release from human blood,  
CC when contacted with it. A specific polypeptide can be used to stimulate  
CC the proliferation or differentiation of chondrocyte cells. The PRO  
CC proteins can be used to determine the presence of tumours and also  
CC susceptibility to tumour development, particularly adrenal, lung, colon,  
CC breast, prostate, rectal, cervical, or liver tumours, in mammalian  
CC subjects. The oligonucleotide probes specific for the PRO nucleic acids  
CC can be used for genetic analysis of individuals with genetic disorders.

XX SQ Sequence 119 AA;  
Query Match 100.0%; Score 644; DB 22; Length 119;  
Best Local Similarity 100.0%; Pred. No. 1.7e-66;  
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDROASRRWLQEGGQCECKDWFRLAP 60  
DB 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDROASRRWLQEGGQCECKDWFRLAP 60  
OY 61 RRRFMTVSGLPKKQCPDHFPGKGVKTRRQRRHRRKRNKSRACQDPLKQCOLRSPFLPL 119  
DB 61 RRRFMTVSGLPKKQCPDHFPGKGVKTRRQRRHRRKRNKSRACQDPLKQCOLRSPFLPL 119  
RESULT 6  
AAG63977  
ID AAG63977 standard; Protein; 119 AA.  
XX  
AC AAG63977;  
XX  
DT 13-NOV-2001 (first entry)  
XX  
DE Amino acid sequence of a human Lng104 polypeptide.  
XX  
XX Human; lung cancer specific gene; LSG; Lng104; lung cancer.  
XX Homo sapiens.  
XX WO200161055-A2.  
XX  
PD 23-AUG-2001.  
XX  
PF 20-FEB-2001; 2001WO-US05674.  
XX  
PR 17-FEB-2000; 2000US-0183188.  
XX  
PA (DIAD-) DIADEXUS INC.  
XX  
PI Chen S, Sun Y, Macina RA;  
XX  
DR WPI; 2001-529917/58.  
DR N-PSDB; AAH77949, AAH77951.  
XX  
PT New lung cancer specific gene for the treatment and diagnosis of lung  
PT cancer -  
XX  
PS Claim 2; Page 115-116; 119pp; English.  
XX  
CC The present sequence is encoded by a human lung cancer specific gene  
CC (LSG), and represents a polypeptide designated Lng104. LSGs are useful  
CC in the treatment and diagnosis of lung cancer. The treatment of lung  
CC cancer comprises the administration of a molecule which down regulates  
CC the expression of an LSG. An immune response can be mounted against a  
CC target cell expressing an LSG. Identification of potential therapeutic  
CC agents for use in imaging and treating lung cancer which comprises  
CC screening molecules for an ability to bind to or decrease expression  
CC of an LSG relative to LSG in the absence of the agent where the ability  
CC of a molecule to bind to the LSG or decrease expression of the LSG is  
CC indicative of the molecule being useful in imaging and treating lung  
CC cancer.  
XX  
SQ Sequence 119 AA;  
Query Match 100.0%; Score 644; DB 22; Length 119;  
Best Local Similarity 100.0%; Pred. No. 1.7e-66;  
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDROASRRWLQEGGQCECKDWFRLAP 60  
DB 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDROASRRWLQEGGQCECKDWFRLAP 60

QY 61 RREKMTVSGLPKPKQCPDHFKGKGVKTRRHQRHRRKPNKHSRACQDFLKCQCLRSFALPL 119  
 Db 61 RREKMTVSGLPKPKQCPDHFKGKGVKTRRHQRHRRKPNKHSRACQDFLKCQCLRSFALPL 119

RESULT 7  
 ID AAB87538 standard; Protein; 119 AA.  
 XX AAB87538;

XX AC AAB87538;  
 XX DT 15-MAY-2001 (first entry)  
 XX DE Human PRO842.

XX KW Human; PRO protein; mapping.

XX OS Homo sapiens.

XX PN WO200116318-A2.

XX PD 08-MAR-2001.

XX PF 24-AUG-2000; 2000WO-US23328.

XX PR 01-SEP-1999; 99WO-US20111.

XX PR 15-SEP-1999; 99WO-US21090.

XX PR 07-DEC-1999; 99US-0169495.

XX PR 09-DEC-1999; 99US-0170262.

XX PR 11-JAN-2000; 2000US-0175481.

XX PR 18-FEB-2000; 2000WO-US04341.

XX PR 18-FEB-2000; 2000WO-US04342.

XX PR 22-FEB-2000; 2000WO-US04414.

XX PR 01-MAR-2000; 2000WO-US05601.

XX PR 03-MAR-2000; 2000US-0187202.

XX PR 25-APR-2000; 2000US-0199397.

XX PR 22-MAY-2000; 2000WO-US14042.

XX PR 05-JUN-2000; 2000US-0209832.

XX PA (GETH ) GENENTECH INC.

XX PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi CJ, Gunney AL, Watanabe CK, Wood WI;

XX DR WPI; 2001-183260/18.

XX DR N-PSDB; AAF92070.

XX PT Eighty four nucleic acids encoding PRO polypeptides, useful in

XX PT molecular biology, including use as hybridization probes, and in

XX PT chromosome and gene mapping.

XX PS Claim 12; Fig 26; 278pp; English.

XX CC The present sequence is a human PRO polypeptide (secreted and

XX CC transmembrane). The PRO protein, and PRO agonists, PRO antagonists or

XX CC anti-PRO antibodies are useful for preparation of a medicament useful in

XX CC the treatment of a condition which is responsive to the PRO protein,

XX CC agonists, antagonists or anti-PRO antibodies. The PRO protein may also be

XX CC employed as molecular weight markers for protein electrophoresis. The PRO

XX CC coding sequence has applications in molecular biology, including use as

XX CC hybridisation probes, and in chromosome and gene mapping.

XX SQ Sequence 119 AA;

Query Match 100.0%; Score 644; DB 22; Length 119;

Best Local Similarity 100.0%; Pred. No. 1.7e-66;

Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISLILLLPLMLMSVSSSLNPGVARGHRDQASRRMLQEGGCECKDMFLRAP 60

Db 1 MKVLISLILLLPLMLMSVSSSLNPGVARGHRDQASRRMLQEGGCECKDMFLRAP 60

QY 61 RREKMTVSGLPKPKQCPDHFKGKGVKTRRHQRHRRKPNKHSRACQDFLKCQCLRSFALPL 119

Db 61 RREKMTVSGLPKPKQCPDHFKGKGVKTRRHQRHRRKPNKHSRACQDFLKCQCLRSFALPL 119

RESULT 8  
 ID AAB65191 standard; Protein; 119 AA.  
 XX AAB65191;

XX AC AAB65191;

XX DT 02-APR-2001 (first entry)

XX DE Human PRO842 (UNQ473) protein sequence SEQ ID NO:165.

XX KW Human; secreted and transmembrane protein; PRO; cytosolic;

XX KW cell death; cancer; chromosomal mapping; gene mapping; tissue typing;

XX KW diagnostic assay.

XX OS Homo sapiens.

XX PN WO200073454-A1.

XX PD 07-DEC-2000.

XX PF 30-MAR-2000; 2000WO-US08439.

XX PR 02-JUN-1999; 99WO-US12252.

XX PR 23-JUN-1999; 99US-0141037.

XX PR 07-JUL-1999; 99US-0143048.

XX PR 20-JUL-1999; 99US-0144758.

XX PR 26-JUL-1999; 99US-0145698.

XX PR 28-JUL-1999; 99US-0146222.

XX PR 17-AUG-1999; 99US-0149396.

XX PR 15-SEP-1999; 99WO-US21090.

XX PR 15-SEP-1999; 99WO-US21547.

XX PR 08-OCT-1999; 99US-0158663.

XX PR 30-NOV-1999; 99WO-US28313.

XX PR 01-DEC-1999; 99WO-US28301.

XX PR 16-DEC-1999; 99WO-US30095.

XX PR 20-DEC-1999; 99WO-US30911.

XX PR 05-JAN-2000; 2000WO-US00219.

XX PR 06-JAN-2000; 2000WO-US00376.

XX PR 11-FEB-2000; 2000WO-US03565.

XX PR 18-FEB-2000; 2000WO-US04341.

XX PR 22-FEB-2000; 2000WO-US04414.

XX PR 24-FEB-2000; 2000WO-US04914.

XX PR 24-FEB-2000; 2000WO-US05004.

XX PR 02-MAR-2000; 2000WO-US05841.

XX PR 15-MAR-2000; 2000WO-US06884.

XX PR 20-MAR-2000; 2000WO-US07377.

XX PA (GETH ) GENENTECH INC.

XX PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;

XX PI Ferrara N, Fong S, Gebler H, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi CJ, Gunney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;

XX PI Roy MA, Stewart TA, Tamas D, Watanabe CK, Williams PM, Wood WI;

XX PI Zhang Z;

XX DR WPI; 2001-032160/04.

XX DR N-PSDB; AAF4147.

XX PT PRO polynucleotides used to produce polypeptides used to target

XX PT bioactive molecules such as toxins, radiolabels or antibodies, to

XX PT specific cells, to cause targeted cell death -

XX PS Claim 12; Fig 99; 935pp; English.

XX CC The present invention describes human secreted and transmembrane PRO

XX CC proteins. The PRO proteins have cytostatic activity. The PRO proteins

XX CC can be used for targeted delivery of bioactive molecules, such as

XX CC toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide

XX CC sequences, and their fragments, can be used as hybridisation probes, in

CC chromosomal and gene mapping, and in the generation of anti-sense RNA  
CC and DNA. They may also be used to produce transgenic animals which are  
CC used to develop and screen therapeutically useful reagents. The PRO  
CC nucleotide and protein sequence can be used for tissue typing and in  
CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.  
CC AAF44270 to AAF44470 represent PCR primers and hybridization probes used  
CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and  
CC AAB65154 to AAB65300 represent human PRO polynucleotide and protein  
CC sequences given in the exemplification of the present invention.

XX Sequence 119 AA:

Query Match 100.0%; Score 644; DB 22; Length 119;  
Best Local Similarity 100.0%; Pred. No. 1,7e-66;  
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLSSLLPLMLMSVSSSLNPGVARGHDSRRRLQEGGCECKDWFLLAP 60  
DB 1 MKVLSSLLPLMLMSVSSSLNPGVARGHDSRRRLQEGGCECKDWFLLAP 60  
QY 61 RRRFTVSGLPKQCPDHFKNVKTQRHRRKPNKHSRACQDFLKQCOLRSFALPL 119  
DB 61 RRRFTVSGLPKQCPDHFKNVKTQRHRRKPNKHSRACQDFLKQCOLRSFALPL 119

RESULT 9

AAV82454  
ID AAV82454 standard; Protein; 97 AA.

XX AAV82454;  
DT 30-JUN-2000 (first entry)

DE Mature human TGC-440 secretory protein SEQ ID NO:7.

XX TGC-440; secretory protein; immunological disease; infectious disease;  
KW pulmonary function disorder; hepatic function disorder; nephrotropic;  
KW gastrointestinal function disorder; antiinflammatory; immunomodulatory;  
KW virucide; hepatotropic; antiasthmatic; antibacterial; vaccine;  
KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;  
KW pneumonia; Helicobacter pylori infection.

OS Homo sapiens.  
XX MO200014226-A1.  
XX 16-MAR-2000.  
XX 02-SEP-1999; 99WO-JP04765.  
XX 03-SEP-1998; 98JP-0250108.  
XX (TAKE ) TAKEDA CHEM IND LTD.

XX Itoh Y, Ogi K, Tanaka H, Kitada C;

XX WPI: 2000-256978/22.  
XX N-PSDB: AAA08345.

PT Secretory protein TGC440, antibodies to it and compounds promoting or  
PT inhibiting its activity for diagnosis and treatment of diseases of the  
PT immune system, lung, kidney, liver and intestinal system  
XX Disclosure: Page 80; 86pp; Japanese.

XX The present sequence represents the mature human secretory protein  
XX TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,  
XX vitucide, hepatotropic, antiasthmatic and antibacterial activities,  
XX and can be used in vaccines. TGC-440 and the polynucleotide sequence  
XX encoding it can be used to treat, prevent and diagnose immunological,  
XX lung, liver, kidney or gastrointestinal disorders and infectious  
XX diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,  
XX pulmonary hypertension, and Helicobacter pylori infection. An antibody

CC immunospecific for TGC-440 is also useful in the above treatment and  
CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid  
CC specimen.

XX Sequence 97 AA:

Query Match 85.1%; Score 548; DB 21; Length 97;  
Best Local Similarity 100.0%; Pred. No. 1.6e-55;  
Matches 97; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 23 SLNPGVARGHDSRRRLQEGGCECKDWFLLAPRRKFTVSGLPKQCPDHFKG 82  
DB 1 SLNPGVARGHDSRRRLQEGGCECKDWFLLAPRRKFTVSGLPKQCPDHFKG 60  
QY 83 NVKTRHQRHRRKPNKHSRACQDFLKQCOLRSFALPL 119  
DB 61 NVKTRHQRHRRKPNKHSRACQDFLKQCOLRSFALPL 97

RESULT 10

AAW83953  
ID AAW83953 standard; Protein; 93 AA.

XX AAW83953;

DT 28-JAN-1999 (first entry)

DE Polypeptide encoded by gene 7 clone HYPD64.

XX Secreted protein; gene therapy; protein therapy; diagnosis; treatment;  
KW central nervous system; CNS; immune system; cancer; trauma; liver;  
KW reproductive disorder; congenital malformation; degenerative disease;  
KW inflammatory disease; neoplasia; metabolic disorder; testis; placenta;  
KW brain; T cell; spleen; lung; heart; thymomastarcoma; endocrine system;  
KW endocrinopathy; endocrine polyglandular syndrome; endocrine; sepsis;  
KW endocrine ophthalmopathy; osteoclastoma; bacterial infection; bone.

OS Homo sapiens.  
XX WO9845712-A2.  
XX 15-OCT-1998.  
XX 07-APR-1998; 98WO-US06801.  
XX 30-MAY-1997; 97US-0048184.  
XX 08-APR-1997; 97US-0042726.  
XX 08-APR-1997; 97US-0042727.  
XX 08-APR-1997; 97US-0042728.  
XX 08-APR-1997; 97US-0042754.  
XX 08-APR-1997; 97US-0042825.  
XX 30-MAY-1997; 97US-0048068.  
XX 30-MAY-1997; 97US-0048070.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Feng P, NI J, Rosen CA, Ruben SM, Yu G;

XX WPI: 1998-594496/50.

PT New isolated human genes and secreted polypeptide(s) they encode -  
PT useful for the diagnosis and treatment of e.g. cancers, CNS  
PT disorders, immune system disorders, inflammatory disease and  
PT bacterial infections

XX Disclosure: Page 10; 142pp; English.

SEQIDNO: 53 (P126)

XX This represents a polypeptide encoded by the nucleic acid molecule  
XX designated Gene 7 from the human cDNA clone HYPD64 (deposited  
XX as clone ATCC 97955 and ATCC 209074) which encodes a human secreted  
XX protein of the invention. The gene is expressed primarily in liver,  
XX spleen, bone marrow and to a lesser extent in amygdala and is useful as  
XX reagents for differential identification of tissues in a biological

CC sample.  
CC The invention relates to 20 novel genes and their fragments (AA69611 to  
CC AA69630) and corresponding secreted proteins (AA68391 to AA68395)  
CC which are useful for preventing, treating or ameliorating medical  
CC conditions e.g. by protein of gene therapy. Also pathological conditions  
CC can be diagnosed by determining the amount of the new polypeptides in a  
CC sample or by determining the presence of mutations in the  
CC polynucleotides. Specific uses are based on which tissues they are most  
CC highly expressed in, and include developing products for the diagnosis or  
CC treatment of central nervous system (CNS) and immune system diseases,  
CC reproductive disorders, cancers, congenital malformations, degenerative  
CC diseases, trauma, inflammatory disease, neoplasia, metabolic disorders,  
CC diseases in testes, placenta, liver, brain and activated T cells, spleen  
CC of the endocrine system or other endocrinopathies, e.g. endocrine  
CC polyglandular syndrome, endocrinoma, and endocrine ophthalmopathy,  
CC osteoclastoma and other bone remodelling disorders, bacterial infections  
CC and sepsis. The polypeptides are also useful for identifying their  
CC binding partners.  
CC  
XX

SO Sequence 93 AA;

Query Match 81.8%; Score 527; DB 19; Length 93;  
Best Local Similarity 100.0%; Pred. No. 4.2e-53;  
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 27 GVANGHEDRGASRRWLOEGGQCECKDMFLRPRKFMVSGLPKKQCPDHFKNVKK 86  
DB 1 GVAAGHEDRGASRRWLOEGGQCECKDMFLRPRKFMVSGLPKKQCPDHFKNVKK 60  
|||  
|||

OY 87 TRHQRHRRKPNKHSRACQFLKQCLRSFALPL 119  
DB 61 TRHQRHRRKPNKHSRACQFLKQCLRSFALPL 93  
|||  
|||

RESULT 11  
AA682457  
ID AAY82457 standard; Protein; 119 AA.

AC AAY82457;

DT 30-JUN-2000 (first entry)

DE Mouse TGC-440 secretory protein SEQ ID NO:3.

XX TGC-440; secretory protein; immunological disease; infectious disease;  
XX pulmonary function disorder; hepatic function disorder; nephrotropic;  
XX gastrointestinal function disorder; antiinflammatory; immunomodulatory;  
XX virucide; hepatotropic; antiasthmatic; antibacterial; vaccine;  
XX hepatitis; nephritis; influenza; asthma; pulmonary hypertension;  
XX pneumonia; Helicobacter pylori infection.  
XX

OS Mus sp.

PN WO200014226-A1.

PD 16-MAR-2000.

PF 02-SEP-1999; 99WO-JP04765.

PR 03-SEP-1998; 98JP-0250108.

PA (TAKE ) TAKEDA CHEM IND LTD.

PI Itoh Y, Ogi K, Tanaka H, Kitada C;

DR WPI: 2000-256978/22.

DR N-PSDB; AAA08349; AAA08350.

XX The present sequence represents the mature mouse secretory protein  
XX inhibiting its activity for diagnosis and treatment of diseases of the  
XX immune system, lung, kidney, liver and intestinal system  
XX

PS Claim 1; Fig 3; 86pp; Japanese.

XX The present sequence represents a mouse secretory protein designated  
XX TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,  
XX virucide, hepatotropic, antiasthmatic and antibacterial activities,  
XX and can be used in vaccines. TGC-440 and the polynucleotide sequence  
XX encoding it can be used to treat, prevent and diagnose immunological,  
XX lung, liver, kidney or gastrointestinal disorders and infectious  
XX diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,  
XX pulmonary hypertension, and Helicobacter pylori infection. An antibody  
XX immunospecific for TGC-440 is also useful in the above treatment and  
XX diagnosis, and also for quantifying the amount of TGC-440 in a liquid  
XX specimen.  
XX

SO Sequence 119 AA;

Query Match 70.8%; Score 456; DB 21; Length 119;  
Best Local Similarity 71.4%; Pred. No. 8.8e-45;  
Matches 85; Conservative 9; Mismatches 25; Indels 0; Gaps 0;

OY 1 MKYISSLILLPLMLMSWSSSLNPGVARGHEDRGASRRWLOEGGQCECKDMFLRAP 60  
DB 1 MKLASFFLLPLVMLMSWSSSPNPGVARGHEDHLPFRRLLEGQCECKDMFLQAP 60  
|||  
|||

OY 61 RRKFMVSGLPKKQCPDHFKNVKKTRHQRHRRKPNKHSRACQFLKQCLRSFALPL 119  
DB 61 KKRATVILGPPRRQCCDHYKGRKRNKRRKRSORPSRACQFLKRLHLSFALPL 119  
|||  
|||

RESULT 12  
AA682458  
ID AAY82458 standard; Protein; 97 AA.

AC AAY82458;

DT 30-JUN-2000 (first entry)

DE Mature mouse TGC-440 secretory protein SEQ ID NO:9.

XX TGC-440; secretory protein; immunological disease; infectious disease;  
XX pulmonary function disorder; hepatic function disorder; nephrotropic;  
XX gastrointestinal function disorder; antiinflammatory; immunomodulatory;  
XX virucide; hepatotropic; antiasthmatic; antibacterial; vaccine;  
XX hepatitis; nephritis; influenza; asthma; pulmonary hypertension;  
XX pneumonia; Helicobacter pylori infection.  
XX

OS Mus sp.

PN WO200014226-A1.

PD 16-MAR-2000.

PF 02-SEP-1999; 99WO-JP04765.

PR 03-SEP-1998; 98JP-0250108.

PA (TAKE ) TAKEDA CHEM IND LTD.

PI Itoh Y, Ogi K, Tanaka H, Kitada C;

DR WPI: 2000-256978/22.

DR N-PSDB; AAA08351.

XX The present sequence represents the mature mouse secretory protein  
XX inhibiting its activity for diagnosis and treatment of diseases of the  
XX immune system, lung, kidney, liver and intestinal system  
XX  
XX Disclosure; Page 81-82; 86pp; Japanese.

XX The present sequence represents the mature mouse secretory protein  
XX TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,  
XX virucide, hepatotropic, antiasthmatic and antibacterial activities,  
XX and can be used in vaccines. TGC-440 and the polynucleotide sequence



CC encoding it can be used to treat, prevent and diagnose immunological,  
 CC lung, liver, kidney or gastrointestinal disorders and infectious  
 CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,  
 CC pulmonary hypertension, and Helicobacter pylori infection. An antibody  
 CC immunospecific for TGC-440 is also useful in the above treatment and  
 CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid  
 CC specimen.  
 SQ Sequence 97 AA:  
 Query Match 59.9%; Score 386; DB 21; Length 97;  
 Best Local Similarity 71.1%; Pred. No. 8,3e-37;  
 Matches 69; Conservative 7; Mismatches 21; Indels 0; Gaps 0;  
 QY 23 SLNPGVANGHRDQASRRMLQEGQCECKDMFLAPRRKMTVSGLPKQCPDHFNG 82  
 1 SPNPGVANGHRDQASRRMLQEGQCECKDMFLAPRRKMTVSGLPKQCPDHFNG 60  
 DB 83 NVKTRHQRHRRKPKHSHRACQFLKQCOLRSPALPL 119  
 61 REKKNRHHKRRKSRACQFLKQCOLRSPALPL 97  
 QY 61 REKKNRHHKRRKSRACQFLKQCOLRSPALPL 97  
 DB 61 REKKNRHHKRRKSRACQFLKQCOLRSPALPL 97  
 RESULT 13  
 AAY82455  
 ID AAY82455 standard; Protein; 119 AA.  
 XX  
 AC AAY82455;  
 XX  
 DT 30-JUN-2000 (first entry)  
 XX  
 DE Rat TGC-440 secretory protein SEQ ID NO:2.  
 XX  
 KM TGC-440: secretory protein; immunological disease; infectious disease;  
 KM pulmonary function disorder; hepatic function disorder; nephrotropic;  
 KM gastrointestinal function disorder; antiinflammatory; immunomodulatory;  
 KM vitruclide; hepatotropic; antiasthmatic; antibacterial; vaccine;  
 KM hepatitis; nephritis; influenza; asthma; pulmonary hypertension;  
 KM pneumonia; Helicobacter pylori infection.  
 XX  
 OS Rattus sp.  
 XX  
 PN WO200014226-A1.  
 XX  
 PD 16-MAR-2000.  
 XX  
 PF 02-SEP-1999; 99WO-JP04765.  
 XX  
 PR 03-SEP-1998; 98JP-0250108.  
 XX  
 PA (TAKE ) TAKEDA CHEM IND LTD.  
 XX  
 PI Itoh Y, Ogi K, Tanaka H, Kitada C;  
 XX  
 DR WPI: 2000-256978/22.  
 DR N-PSDB; AAA08346; AAA08347.  
 XX  
 PT Secretory protein TGC440, antibodies to it and compounds promoting or  
 PT inhibiting its activity for diagnosis and treatment of diseases of the  
 PT immune system, lung, kidney, liver and intestinal system  
 XX  
 PS Claim 1; Fig 2; 86pp; Japanese.  
 XX  
 CC The present sequence represents a rat secretory protein designated  
 CC TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,  
 CC vitruclide, hepatotropic, antiasthmatic and antibacterial activities,  
 CC and can be used in vaccines. TGC-440 and the polynucleotide sequence  
 CC encoding it can be used to treat, prevent and diagnose immunological,  
 CC lung, liver, kidney or gastrointestinal disorders and infectious  
 CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,  
 CC pulmonary hypertension, and Helicobacter pylori infection. An antibody  
 CC immunospecific for TGC-440 is also useful in the above treatment and  
 CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid

CC specimen.  
 XX  
 SQ Sequence 119 AA:  
 Query Match 59.9%; Score 386; DB 21; Length 119;  
 Best Local Similarity 63.0%; Pred. No. 1,1e-36;  
 Matches 75; Conservative 10; Mismatches 34; Indels 0; Gaps 0;  
 QY 1 MKVLISLLLLPLMIMSVSSSLNPGVARGHRDQASRRMLQEGQCECKDMFLAP 60  
 1 MKVLISPLILLLTGMFTATVSSSPNOEVARHHDQDQAPRRWMEGQEDCDMSLRVS 60  
 DB 61 RRFMTVSGLPKQCPDHFNGKVKTRHQRHRRKPKHSHRACQFLKQCOLRSPALPL 119  
 61 KRTTATVLEPPRRKQCPDHFNGKVKTRHQRHRRKPKHSHRACQFLKQCOLRSPALPL 119  
 RESULT 14  
 AAY11732  
 ID AAY11732 standard; Protein; 69 AA.  
 XX  
 AC AAY11732;  
 XX  
 DT 18-JUN-1999 (first entry)  
 XX  
 DE Human 5' EST secreted protein SEQ ID No: 332.  
 XX  
 KM Human; secreted protein; EST; expressed sequence tag; diagnosis;  
 KM forensic; gene therapy; chromosome mapping; signal peptide; prostate;  
 KM upstream regulatory sequence; cytokine activity; cell proliferation;  
 KM differentiation; haematopoiesis regulation; tissue growth regulation;  
 KM reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;  
 KM thrombolytic; anti-inflammatory; tumour inhibition.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO9906550-A2.  
 XX  
 PD 11-FEB-1999.  
 XX  
 PF 31-JUL-1998; 98WO-1B01232.  
 XX  
 PR 01-AUG-1997; 97US-0905144.  
 XX  
 PA (GEST ) GENSET.  
 XX  
 PI Duclert A, Dumas Milne Edwards J, Lacroix B;  
 XX  
 DR WPI: 1999-153780/13.  
 DR N-PSDB; AAX40454.  
 XX  
 PT New isolated prostate-derived nucleic acids - used to develop  
 PT products which may have cytokine, immune regulatory, haematopoiesis  
 PT regulating, anti-inflammatory or tumour inhibition activity  
 XX  
 PS Claim 34; Page 512; 675pp; English.  
 XX  
 CC AAX40438 to AAX40715 represent 5' expressed sequence tags (ESTs) for  
 CC human secreted proteins expressed in prostate, and encode the proteins  
 CC given in AAY11716 to AAY11993 respectively. The proteins given represent  
 CC the signal peptide and an N-terminal fragment of a secreted protein. The  
 CC nucleic acid sequences can be used for producing secreted human gene  
 CC products. They can also be used to develop products for diagnosis and  
 CC therapy. The proteins obtained may have cytokine activity, cell  
 CC proliferation and differentiation activity, haematopoiesis regulating  
 CC activity, tissue growth regulating activity, reproductive hormone  
 CC regulating activity, chemotactic/chemokinetic activity, haemostatic and  
 CC thrombolytic activity, receptor/ligand activity, anti-inflammatory  
 CC activity, tumour inhibition activity or other activities. The products  
 CC can be used in forensic, gene therapy and chromosome mapping procedures.  
 CC The sequences can also be used for obtaining corresponding promoter  
 CC sequences. The nucleic acids encoding the signal peptides can be used for  
 CC directing extracellular secretion of a polypeptide or the insertion of a

CC polypeptide into a membrane, or importing a polypeptide into a cell.  
XX  
SQ Sequence 69 AA;

Query Match 55.6%; Score 358; DB 20; Length 69;  
Best Local Similarity 100.0%; Pred. No. 9,4e-34;  
Matches 63; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRRGQASRRWLQGGQCECKDFLRAP 60  
DB 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRRGQASRRWLQGGQCECKDFLRAP 60

QY 61 RRRKFTVSG 69  
DB 61 RRRKFTVSG 69

RESULT 15

AAV82456  
ID AAV82456 standard; Protein; 97 AA.

AC AAV82456;

DT 30-JUN-2000 (first entry)

DE Mature rat TGC-440 secretory protein SEQ ID NO:8.

XX TGC-440; secretory protein; immunological disease; infectious disease;  
XX pulmonary function disorder; hepatic function disorder; nephrotropic;  
XX gastrointestinal function disorder; antiinflammatory; immunomodulatory;  
XX virucide; hepatotropic; antiasthmatic; antibacterial; vaccine;  
XX hepatitis; nephritis; influenza; asthma; pulmonary hypertension;  
XX pneumonia; Helicobacter pylori infection.

OS Rattus sp.

PN WO200014226-A1.

PD 16-MAR-2000.

PF 02-SEP-1999; 99WO-JP04765.

PR 03-SEP-1998; 98JP-0250108.

XX (TAKE ) TAKEDA CHEM IND LTD.

PI Itoh Y, Ogi K, Tanaka H, Kitada C;

DR WPI: 2000-256978/22.

XX N-PSDB; AAA08348.

PT Secretory protein TGC440, antibodies to it and compounds promoting or  
PT inhibiting its activity for diagnosis and treatment of diseases of the  
PT immune system, lung, kidney, liver and intestinal system

PS Disclosure: Page 81; 86pp; Japanese.

XX The present sequence represents a mature rat secretory protein designated  
CC TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,  
CC virucide, hepatotropic, antiasthmatic and antibacterial activities,  
CC and can be used in vaccines. TGC-440 and the polynucleotide sequence  
CC encoding it can be used to treat, prevent and diagnose immunological,  
CC lung, liver, kidney or gastrointestinal disorders and infectious  
CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,  
CC pulmonary hypertension, and Helicobacter pylori infection. An antibody  
CC immunospecific for TGC-440 is also useful in the above treatment and  
CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid  
CC specimen.

SQ Sequence 97 AA;

Query Match 53.1%; Score 342; DB 21; Length 97;  
Best Local Similarity 64.9%; Pred. No. 9.9e-32;

Matches 63; Conservative 8; Mismatches 26; Indels 0; Gaps 0;

QY 23 SLNPGVARGHRRGQASRRWLQGGQCECKDFLRAPRRKFTVSGLPKKQCECHFKG 82

DB 1 SPNDEVARHHGGDQDAPRRWLMEGGQCECDCKDWSLRKRTTAVLEPPKQCECHFKG 60

QY 83 NYKKTTRQRRHRRKPKMHSRACQOFLKQCLRSFALPL 119

DB 61 SEKKNRQKHRRKKSQRPSTCQOFLKRCQLASFALPL 97

Search completed: April 16, 2003, 12:15:12

Job time : 38 secs